Treatment News : Battle of the Integrase Inhibitors: Dolutegravir Bests Isentress

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 11, 2013

Battle of the Integrase Inhibitors: Dolutegravir Bests Isentress

Given to HIV-positive people who are treatment-experienced, ViiV Healthcare’s investigational integrase inhibitor dolutegravir has proved superior to Isentress (raltegravir), an approved drug in the same class of antiretrovirals (ARVs), aidsmap reports. Investigators conduced a 48-week, Phase III trial comparing the two drugs in 724 people with HIV who were on failing ARV regimens and had ongoing viral replication. They announced their findings at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur and also published their study online in The Lancet.

Everyone in the study had drug resistance to two or more classes of ARVs and had not yet taken an integrase inhibitor. At the outset of the study, the median CD4 count was about 200, and 30 percent of the people had a viral load greater than 50,000. The participants were randomly divided into two groups: One was given once-daily dolutegravir, the other twice-daily Isentress. All participants took background regimens selected by the investigators including no more than two ARVs, with at least one of the drugs fully active against the virus.

After 48 weeks, 71 percent of those taking dolutegravir had an undetectable viral load, compared with 64 percent of the participants in the Isentress group. This was a statistically significant difference, meaning it was unlikely to have occurred by chance. Six percent of the dolutegravir group experienced virologic failure, a figure that was doubled for those taking Isentress, at 12 percent. Just 1 percent of those on dolutegravir developed mutations resistant to integrase inhibitors, compared with 5 percent of those in the Isentress group.

CD4 gains between the two groups, however, were about equivalent, with levels increasing by a respective 162 and 153 cells in the dolutegravir and Isentress groups.

To read the aidsmap story, click here.

To read the conference abstract, click here.

To read the Lancet abstract, click here.

Search: Integrase inhibitors, dolutegravir, Isentress, raltegravir, antiretrovirals, HIV, The Lancet, 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, IAS 2013.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    RyGuy00
    New York
    New York


    Fred9774
    Brooklyn
    New York


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.